SCHEMBL4032588

SCHEMBL4032588

CCOC(=O)N1CCN(CCCn2c3c(c4cc(C(=O)OC)ccc42)CCCC3)CC1

nearest known ligand 0.61

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ SCARB1 Q8WTV0 3/20 0.61
▸ HSD17B10 Q99714 1/20 0.46
▸ HRH2 P25021 6/20 0.44
▸ HRH1 P35367 6/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ AKR1B10 O60218 1/20 0.42
▸ AKR1B1 P15121 1/20 0.42
▸ CNR2 P34972 1/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ KMT2A Q03164 3/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ MEN1 O00255 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4030252 0.81 SCARB1 (0.70) SCARB1HSD17B10KDM4ENPC1ALDH1A1
SCHEMBL13746624 0.81 SCARB1 (0.60) SCARB1HSD17B10KDM4ECNR2NPC1
SCHEMBL4030106 0.80 SCARB1 (0.61) SCARB1HSD17B10KDM4ENPC1KMT2A
SCHEMBL4189175 0.80 SCARB1 (0.69) SCARB1HSD17B10KDM4ENPC1ALDH1A1
SCHEMBL4028758 0.80 SCARB1 (0.72) SCARB1HSD17B10CNR2NPC1
SCHEMBL4024931 0.80 SCARB1 (0.69) SCARB1HSD17B10KDM4ENPC1ALDH1A1
SCHEMBL4030140 0.80 SCARB1 (0.59) SCARB1HSD17B10KDM4ENPC1ALDH1A1
SCHEMBL4027183 0.80 SCARB1 (0.70) SCARB1HSD17B10KDM4EKMT2AALDH1A1
SCHEMBL4029504 0.80 SCARB1 (0.68) SCARB1HSD17B10KDM4ENPC1ALDH1A1
SCHEMBL4195549 0.80 SCARB1 (0.68) SCARB1HSD17B10KDM4ENPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009103022-A1 DERIVATIVES OF SUBSTITUTED FUSED RING CYCLOINDOLES AND METHODS OF THEIR USE ITHERX PHARMACEUTICALS, INC. (US) 2009-08-20 — — WO disclosed
Send feedback